Hydroxyurée (HU) résistance ou intolérance dans la thrombocythémie essentielle (ET), déclencheur...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

ID	`RF-ET-HU-RESISTANT-INTOLERANT`
Type	Signal d’alerte
État	examiné 2026-05-08
Maladies	`DIS-ET`
Sources	`SRC-ESMO-MPN-2015` `SRC-NCCN-MPN-2025`

Origine du drapeau rouge

Définition	Hydroxyurea (HU) resistance or intolerance in essential thrombocythemia (ET), triggering switch to 2L cytoreduction. ELN/BCSH resistance criteria: platelets ≥600 ×10⁹/L despite HU ≥2 g/day for ≥3 months; failure to achieve platelet <400 ×10⁹/L AND WBC <10 ×10⁹/L on adequate HU dose; thrombotic event occurring on HU therapy. ELN intolerance criteria: ANC <1 ×10⁹/L or Hgb <10 g/dL on any dose of HU; HU-related mucocutaneous toxicity (oral ulcers, leg ulcers, skin atrophy) grade ≥2 at any dose; fever ≥38°C attributable to HU. Anagrelide is the ELN/NCCN 2L standard after HU failure — platelet- selective, non-leukemogenic, preferred in younger patients (ANAHYDRET trial: anagrelide non-inferior to HU in event-free survival, better arterial thrombosis rate). Pegylated IFN (ropeginterferon) is the preferred alternative in pregnancy/planning or JAK2-V617F dominant disease but is not yet a separa...
Direction clinique	désescalade
Catégorie	prior-therapy-class
Algorithme de décalage	ALGO-ET-2L

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "hu_resistance",
      "value": true
    },
    {
      "finding": "hydroxyurea_resistance",
      "value": true
    },
    {
      "finding": "hu_intolerance",
      "value": true
    },
    {
      "finding": "hydroxyurea_intolerance",
      "value": true
    },
    {
      "finding": "cytoreduction_failure_class",
      "value": "HU"
    },
    {
      "finding": "cytoreduction_failure_class",
      "value": "hydroxyurea"
    },
    {
      "finding": "hu_status",
      "value": "resistant"
    },
    {
      "finding": "hu_status",
      "value": "intolerant"
    },
    {
      "finding": "thrombosis_on_hu",
      "value": true
    },
    {
      "comparator": ">=",
      "condition_context": "on_max_tolerated_hu_3mo",
      "finding": "platelet_on_hu",
      "threshold": 600
    }
  ],
  "type": "prior_therapy_failure"
}

Notes

Note: ALGO-ET-2L step 2 already includes RF-PV-ET-HIGH-THROMBOSIS-RISK in its any_of — this RF augments (not replaces) that gate, adding the explicit HU-failure criterion. Since anagrelide is the only 2L IND in the KB, both true and false branches at step 2 route to anagrelide; the RF primarily provides trace evidence for why the switch was made. Age <60 preferring non-cytotoxic option is a clinical preference condition not mapped to a finding — retained as free-text in the algo. Step 3 is degenerate (both → anagrelide) and intentionally not wired. Missing IND-ET-2L-PEG-IFN: peg-IFN α-2a / ropeginterferon is the preferred 2L in pregnancy or JAK2-driven disease (ELN 2018, BSH 2024) but is not modeled — flagged as OOS gap in the algo notes. Draft pending two-reviewer clinical co-lead signoff (CHARTER §6.1).

Utilisé par

Algorithmes

ALGO-ET-2L - ALGO-ET-2L